We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Deep-Sea Microbe Provides Rich Source of Anticancer Molecule
News

Deep-Sea Microbe Provides Rich Source of Anticancer Molecule

Deep-Sea Microbe Provides Rich Source of Anticancer Molecule
News

Deep-Sea Microbe Provides Rich Source of Anticancer Molecule

Salinispora cultures in the Moore Lab at UC San Diego's Scripps Institution of Oceanography. These bacterial cultures produce salinosporamide A, a potent anticancer currently in phase III clinical trials to treat glioblastoma. Credit: Erik Jepsen/ UC San Diego
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Deep-Sea Microbe Provides Rich Source of Anticancer Molecule"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule.


The anti-cancer molecule salinosporamide A, also called Marizomb, is in Phase III clinical trials to treat glioblastoma, a brain cancer. Scientists now for the first time understand the enzyme-driven process that activates the molecule.


Researchers at UC San Diego’s Scripps Institution of Oceanography found that an enzyme called SalC assembles what the team calls the salinosporamide anti-cancer “warhead.” Scripps graduate student Katherine Bauman is the lead author of a paper that explains the assembly process in the March 21 issue of Nature Chemical Biology.


The work solves a nearly 20-year riddle about how the marine bacterium makes the warhead that is unique to the salinosporamide molecule and opens the door to future biotechnology to manufacture new anti-cancer agents.


“Now that scientists understand how this enzyme makes the salinosporamide A warhead, that discovery could be used in the future to use enzymes to produce other types of salinosporamides that could attack not only cancer but diseases of the immune system and infections caused by parasites,” said co-author Bradley Moore, a Distinguished Professor at Scripps Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences.


Salisporamide has a long history at Scripps and UC San Diego. Microbiologist Paul Jensen and marine chemist Bill Fenical of Scripps Oceanography discovered both salinosporamide A and the marine organism that produces the molecule after collecting the microbe from sediments of the tropical Atlantic Ocean in 1990. Some of the clinical trials over the course of the drug’s development took place at Moores Cancer Center at UC San Diego Health.


“This has been a very challenging 10-year project,” said Moore, who is Bauman’s advisor. “Kate’s been able to bring together 10 years’ worth of earlier work to get us across the finish line.”


A big question for Bauman was to find out how many enzymes were responsible for folding the molecule into its active shape. Are multiple enzymes involved or just one?


“I would have bet money on more than one. In the end, it was just SalC. That was surprising,” she said.


Moore says the salinosporamide molecule has a special ability to cross the blood-brain barrier, which accounts for its progress in clinical trials for glioblastoma. The molecule has a small but complex ring structure. It starts as a linear molecule that folds into a more complex circular shape.


“The way nature makes it is beautifully simple. We as chemists can’t do what nature has done to make this molecule, but nature does it with a single enzyme,” he said.


The enzyme involved is common in biology; it is one that participates in the production of fatty acids in humans and antibiotics like erythromycin in microbes.


Bauman, Percival Yang-Ting Chen of Morphic Therapeutics in Waltham, Mass., and Daniella Trivella of Brazil’s National Center for Research in Energy and Materials, determined the molecular structure of SalC. For this purpose they used the Advanced Light Source, a powerful particle accelerator that generates x-ray light, at the U.S. Department of Energy’s Lawrence Berkeley National Laboratory. 


“The SalC enzyme performs a reaction very different from a normal ketosynthase,” Bauman said. A normal ketosynthase is an enzyme that helps a molecule form a linear chain. SalC, by contrast, manufactures salinosporamide by forming two complex, reactive, ring structures.


A single enzyme can form both of those ring structures that are hard for synthetic chemists to make in the lab. Armed with this information, scientists now can mutate the enzyme until they find forms that show promise for suppressing various types of disease.


The marine bacterium involved, called Salinispora tropica, makes salinosporamide to avoid being eaten by its predators. But scientists have found that salinosporamide A also can treat cancer. They have isolated other salinosporamides, but salinosporamide A has features that the others lack – including biological activity that makes it hazardous to cancer cells.


“Inhibiting that proteasome makes it a great anti-cancer agent,” said Bauman, speaking of the protein complex that degrades useless or impaired proteins. But there’s another type of proteasome found in immune cells. What if scientists could devise a slightly different salinosporamide than salinosporamide A? One that poorly inhibits the cancer-prone proteasome but excels at inhibiting the immunoproteasome? Such a salinosporamide could be a highly selective treatment for autoimmune diseases, the type that causes the immune system to turn upon the very body it should protect.


“That’s the idea behind generating some of these other salinosoporamides. And access to this enzyme SalC that installs the complicated ring structure opens the door to that in the future,” Bauman said.


Reference: Bauman KD, Shende VV, Chen PYT, et al. Enzymatic assembly of the salinosporamide γ-lactam-β-lactone anticancer warhead. Nat Chem Biol. 2022:1-9. doi: 10.1038/s41589-022-00993-w


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

 
Advertisement